Hai-Ping Mei, MD
Physical Medicine & Rehabilitation · Wyomissing, PANPI 1073567087
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 26.1% of the total. Reporting peaked in 2019 at $237 and has fallen 83.6% since, to $39 in 2025.
Across 24 payments — averaging $20.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$129
- Merz Pharmaceuticals, LLC$83
- Merz North America, Inc.$47
- Ipsen Biopharmaceuticals, Inc$47
- Avanir Pharmaceuticals, Inc.$30
- Arbor Pharmaceuticals, Inc.$27
- plus $131 from 7 others
What the payments were for
- Food & beverage$494100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 7 | $129 |
| Merz Pharmaceuticals, LLC | 2 | $83 |
| Merz North America, Inc. | 2 | $47 |
| Ipsen Biopharmaceuticals, Inc | 2 | $47 |
| Avanir Pharmaceuticals, Inc. | 2 | $30 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Microtransponder, Inc. | 1 | $24 |
| Celularity Inc. | 1 | $23 |
| Sanofi | 1 | $21 |
| Medtronic | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Assertio Therapeutics, Inc. | 1 | $14 |
| Pacira Therapeutics, Inc. | 1 | $13 |
How this compares
$494 in reported general payments places this provider in the 70th percentile of 550 physical medicine & rehabilitation providers in Pennsylvania.
See all physical medicine & rehabilitation providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 26 | $14,155 |
| Gabapentin | 81 | $1,131 |
| Naloxone Hcl | 11 | $843 |
| Pantoprazole Sodium | 17 | $165 |
| Metoprolol Succinate | 23 | $142 |
| ClopidogrelClopidogrel Bisulfate | 32 | $102 |
| Oxycodone Hcl | 21 | $89 |
| Metoprolol Tartrate | 17 | $87 |
| Atorvastatin Calcium | 13 | $85 |
| Tramadol Hcl | 17 | $36 |
| Furosemide | 12 | $33 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Wyomissing
- Jeffery RoweKing Of Prussia$1.9M
- Michael SaulinoElkins Park$425K
- Huaguang QuChalfont$356K
- Alberto EsquenaziPhiladelphia$305K
- Mitchell PaulinPaoli$229K
- Kimberly HeckertPhiladelphia$119K
- David LichtenReading$117K
- Gay WilcherRidley Park$81K
- Jessica MulhernPaoli$79K
- Leonard KamenElkins Park$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.